Pharmaceutical firms paid thousands to attend meetings of panel that advises the FDA on pain killers

drugs

Again, marijuana or cannabis, for many an effective, non-opiate (non-physically addictive), nearly free treatment for pain is widely illegal in this country. One can however get a prescription for Oxycodone, aka hillbilly heroin, which is viciously addictive and expensive no problem.  Such opiates are profitable so long as the effective, largely non-addicting, non-stupefying, nearly free option is kept out of the hands of those who want to obey the law.

I wonder why the pharmaceutical companies would pay thousands of dollars to attend a conference which might determine the FDA’s pain killer policy?

(From The Washington Post)

Even as the meetings were taking place, the idea of FDA officials meeting with firms that had paid big money for an invitation raised eyebrows for some. In an e-mail to organizers, an official from the National Institutes of Health worried whether the arrangements made it look as if the private meetings were a “pay to play process.”

FDA officials did not benefit financially from their participation in the meetings, the agency said. But two later went on to work as pharmaceutical consultants and more than this, the critics said, the e-mails portray an agency that, by allowing itself to get caught up in a panel that seemed to promise influence for money, had blurred the line between the regulators and the regulated.

Click here for the article.